Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care
2024

Comparing Ticagrelor and Prasugrel for Heart Attack Treatment

Sample size: 17642 publication 10 minutes Evidence: high

Author Information

Author(s): Krüger Nils MD, Krefting Johannes MD, Kessler Thorsten MD, Schmieder Raphael MD, Starnecker Fabian MD, Dutsch Alexander MD, Graesser Christian MD, Meyer-Lindemann Ulrike MD, Storz Theresa MD, Pugach Irina PhD, Frieß Christian MD, Chen Zhifen PhD, Bongiovanni Dario MD, Manea Iulian BSc, Dreischulte Tobias PhD, Offenborn Frank, Krase Peter, Sager Hendrik B. MD, Wiebe Jens MD, Kufner Sebastian MD, Xhepa Erion MD PhD, Joner Michael MD, Trenkwalder Teresa MD, Gueldener Ulrich PhD, Kastrati Adnan MD, Cassese Salvatore MD, Schunkert Heribert MD, von Scheidt Moritz MD

Primary Institution: German Heart Center Munich, Technical University of Munich

Hypothesis

Is prasugrel associated with improved cardiovascular outcomes compared to ticagrelor in routine clinical care for individuals with acute coronary syndrome?

Conclusion

Prasugrel was associated with lower rates of all-cause mortality, myocardial infarction, or stroke compared to ticagrelor in individuals with acute coronary syndrome undergoing invasive treatment.

Supporting Evidence

  • In this study, prasugrel was associated with a significantly lower incidence of the primary composite end point compared to ticagrelor.
  • Prasugrel showed better outcomes particularly in patients with ST-segment elevation myocardial infarction.
  • The study used a large sample size of 17,642 matched individuals to ensure robust results.
  • Results were consistent with previous randomized clinical trials that favored prasugrel over ticagrelor.

Takeaway

This study found that prasugrel is better than ticagrelor for heart attack patients who need surgery, helping them live longer and avoid more heart problems.

Methodology

This cohort study used secondary data from a German health insurance claims database and employed 1:1 propensity score matching to compare outcomes between new users of ticagrelor and prasugrel.

Potential Biases

Potential confounding by indication exists as the choice of medication was at the discretion of the treating physician.

Limitations

The study's observational design limits causal inference and may be affected by confounding factors.

Participant Demographics

Mean age was 63.1 years, with 73.9% male participants.

Statistical Information

P-Value

1.24

Confidence Interval

1.12-1.37

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1001/jamanetworkopen.2024.48389

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication